NOVIMMUNE S.A.
BiotechNOVIMMUNE S.A. is a biotechnology company focused on Immunology, Oncology.
FDA Novel Drug Designations
(2018)See 1 novel approval →
NOVIMMUNE S.A.'s Key Drugs
NOVIMMUNE S.A.'s core commercial portfolio centers on GAMIFANT, spanning Immunology and Oncology — its most strategically important drugs approved in the last 15 years.
NOVIMMUNE S.A.'s Recent FDA Approvals
New NDA/BLA approvals for NOVIMMUNE S.A. over the last two years — novel drugs only, excluding generics and label supplements.
NOVIMMUNE S.A.'s Therapeutic Areas
NOVIMMUNE S.A.'s approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NOVIMMUNE S.A.'s Top Competitors
NOVIMMUNE S.A.'s closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NOVIMMUNE S.A. Pipeline Snapshot
NOVIMMUNE S.A. has 3 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 2 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • GAMIFANT leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2018-11-20
- Latest
- 2026-03-17
- Applications
- 1